Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts
Rhea-AI Summary
Opus Genetics (Nasdaq: IRD) will host a virtual R&D Science Forum on June 16, 2026, from 10:00 am–12:00 pm ET. Management and external experts will discuss its multi-asset gene therapy pipeline for inherited retinal diseases, including programs targeting RDH12, MERTK, RHO, LCA5 and BEST1.
Positive
- None.
Negative
- None.
News Market Reaction – IRD
In the Jun 2 session, IRD declined 3.16%, reflecting a moderate negative market reaction. Argus tracked a peak move of +2.0% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 28 | Inducement option grants | Neutral | +3.8% | Reported Nasdaq Rule 5635(c)(4) inducement equity grants for new employees. |
| May 27 | Conference presentation | Neutral | +1.2% | Announced upcoming appearance at the 2026 Jefferies Global Healthcare Conference. |
| May 13 | Conference presentation | Neutral | -2.9% | Disclosed plans to present at RBC Capital Markets 2026 Global Healthcare Conference. |
| May 12 | Quarterly earnings update | Neutral | +1.2% | Reported Q1 2026 financials and detailed pipeline milestones and timelines. |
| May 07 | Clinical data update | Positive | -6.9% | Presented ARVO 2026 clinical/preclinical data showing functional gains across IRD programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company updates, including conferences and data presentations, have generally seen modest price reactions, with one notable divergence where positive ARVO data coincided with a larger share decline.
Over the last month, Opus Genetics has reported Q1 2026 results, multiple conference presentations, inducement grants, and ARVO 2026 data. Financial updates highlighted higher losses but ongoing pipeline progress, while ARVO data showed encouraging efficacy signals across LCA5, BEST1, and RHO programs. Price reactions were mostly modestly positive or slightly negative, except for a -6.9% move on strong ARVO data, indicating occasional disconnects between scientific news and short-term trading. Today’s R&D forum announcement fits this stream of ongoing visibility efforts.
Key Terms
gene therapies medical
inherited retinal diseases medical
clinical testing medical
webcast technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced the guest speakers for its virtual Research & Development (R&D) Science Forum to be held on Tuesday, June 16, 2026, from 10:00 am – 12:00 pm ET.
The R&D Science Forum will feature management and key opinion leaders (KOLs) highlighting Opus Genetics’ multi-asset gene therapy pipeline, which is designed to address the underlying genetic causes of severe IRDs. The Forum will include detailed information on three gene therapy programs entering clinical testing, targeting the RDH12, MERTK, and RHO mutations. In addition, there will be a summary of recently presented data from the ongoing LCA5 and BEST1 clinical programs and an overview of IRD global market opportunities and patient prevalence.
“Our R&D Science Forum brings together leading investigators and scientific experts to highlight the progress we are making within our gene therapy pipeline for inherited retinal diseases,” said George Magrath, M.D., Chief Executive Officer, Opus Genetics. “With significant unmet needs across RDH12, MERTK, RHO, LCA5 and BEST1, we look forward to sharing our preclinical data, our deepening engagement with the clinical community, as well as our strategic development plans as we advance potentially transformative therapies for patients at risk of vision loss.”
Opus Genetics’ R&D Science Forum Guest Speakers:
- Jean Bennett, MD, PhD
Emeritus Professor of Ophthalmology, University of Pennsylvania / Scheie Eye Institute
- Todd Durham, PhD
Senior Vice President, Clinical & Outcomes Research, Foundation Fighting Blindness
- Kenneth C. Fan, MD, MBA
Retina Specialist & Surgeon, Retina Consultants of Texas
- Bart P. Leroy, MD, PhD
Professor of Ophthalmology & Head of Department, Ghent University Hospital
- Robert E. MacLaren, MB ChB, DPhil
Professor of Ophthalmology, University of Oxford
- Lejla Vajzovic, MD
Professor of Ophthalmology, Duke University Eye Center
Webcast Registration:
Registration for the event is available on the Events page of the Opus Genetics website. There will also be an archived replay available following the event.
About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RDH12, MERTK, RHO, CNGB1 and NMNAT1. The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.
Contacts:
Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
Source: Opus Genetics, Inc.
